Medical Care
Global Oncolytic Virus CDMO Services Market Research Report 2025
- May 12, 25
- ID: 237392
- Pages: 86
- Figures: 85
- Views: 2
The global market for Oncolytic Virus CDMO Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Oncolytic virus CDMO service is a customized service provided to customers for the development and production of oncolytic virus vectors.
Oncolytic viruses (OVs) therapy is a new approach to treating tumors, which works by directly killing tumor cells and inducing the body"s immune response. However, natural oncolytic viruses have certain limitations. Therefore, various viruses need to be used as vectors to enhance or weaken viral virulence through genetic modification and introduce new functional genes to improve their oncolytic effect. Currently, herpes simplex virus, adenovirus, vaccinia virus, vesicular stomatitis virus, measles virus, mumps virus, polio virus, etc. can be used as oncolytic virus vectors. These viral vectors can target and kill different tumor cells through different genetic modification methods, achieving better oncolytic effects.
Oncolytic virus CDMO services can accelerate the R&D and production process of oncolytic viruses, provide customers with high-quality oncolytic virus products, and promote innovation in the field of tumor treatment.
North American market for Oncolytic Virus CDMO Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Oncolytic Virus CDMO Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Oncolytic Virus CDMO Services in R&D is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Oncolytic Virus CDMO Services include Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, Creative Biolabs, Takara Bio, Libentech, ABL, Nabios, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus CDMO Services.
The Oncolytic Virus CDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncolytic Virus CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Virus CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recipharm (Vibalogics)
IDT Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
Creative Biolabs
Takara Bio
Libentech
ABL
Nabios
Halix
Obio Technology
Porton Advanced
WuXi ATU
Genevoyager
Segment by Type
Oncolytic Herpes Simplex Virus
Oncolytic Adenovirus
Oncolytic Vaccinia Virus
Others
Segment by Application
R&D
Biopharmaceutical Manufacturers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncolytic Virus CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Oncolytic virus CDMO service is a customized service provided to customers for the development and production of oncolytic virus vectors.
Oncolytic viruses (OVs) therapy is a new approach to treating tumors, which works by directly killing tumor cells and inducing the body"s immune response. However, natural oncolytic viruses have certain limitations. Therefore, various viruses need to be used as vectors to enhance or weaken viral virulence through genetic modification and introduce new functional genes to improve their oncolytic effect. Currently, herpes simplex virus, adenovirus, vaccinia virus, vesicular stomatitis virus, measles virus, mumps virus, polio virus, etc. can be used as oncolytic virus vectors. These viral vectors can target and kill different tumor cells through different genetic modification methods, achieving better oncolytic effects.
Oncolytic virus CDMO services can accelerate the R&D and production process of oncolytic viruses, provide customers with high-quality oncolytic virus products, and promote innovation in the field of tumor treatment.
North American market for Oncolytic Virus CDMO Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Oncolytic Virus CDMO Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Oncolytic Virus CDMO Services in R&D is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Oncolytic Virus CDMO Services include Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, Creative Biolabs, Takara Bio, Libentech, ABL, Nabios, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus CDMO Services.
The Oncolytic Virus CDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncolytic Virus CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Virus CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recipharm (Vibalogics)
IDT Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
Creative Biolabs
Takara Bio
Libentech
ABL
Nabios
Halix
Obio Technology
Porton Advanced
WuXi ATU
Genevoyager
Segment by Type
Oncolytic Herpes Simplex Virus
Oncolytic Adenovirus
Oncolytic Vaccinia Virus
Others
Segment by Application
R&D
Biopharmaceutical Manufacturers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncolytic Virus CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus CDMO Services Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oncolytic Herpes Simplex Virus
1.2.3 Oncolytic Adenovirus
1.2.4 Oncolytic Vaccinia Virus
1.2.5 Others
1.3 Market by Application
1.3.1 Global Oncolytic Virus CDMO Services Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 R&D
1.3.3 Biopharmaceutical Manufacturers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus CDMO Services Market Perspective (2020-2031)
2.2 Global Oncolytic Virus CDMO Services Growth Trends by Region
2.2.1 Global Oncolytic Virus CDMO Services Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oncolytic Virus CDMO Services Historic Market Size by Region (2020-2025)
2.2.3 Oncolytic Virus CDMO Services Forecasted Market Size by Region (2026-2031)
2.3 Oncolytic Virus CDMO Services Market Dynamics
2.3.1 Oncolytic Virus CDMO Services Industry Trends
2.3.2 Oncolytic Virus CDMO Services Market Drivers
2.3.3 Oncolytic Virus CDMO Services Market Challenges
2.3.4 Oncolytic Virus CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus CDMO Services Players by Revenue
3.1.1 Global Top Oncolytic Virus CDMO Services Players by Revenue (2020-2025)
3.1.2 Global Oncolytic Virus CDMO Services Revenue Market Share by Players (2020-2025)
3.2 Global Oncolytic Virus CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oncolytic Virus CDMO Services Revenue
3.4 Global Oncolytic Virus CDMO Services Market Concentration Ratio
3.4.1 Global Oncolytic Virus CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus CDMO Services Revenue in 2024
3.5 Global Key Players of Oncolytic Virus CDMO Services Head office and Area Served
3.6 Global Key Players of Oncolytic Virus CDMO Services, Product and Application
3.7 Global Key Players of Oncolytic Virus CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus CDMO Services Breakdown Data by Type
4.1 Global Oncolytic Virus CDMO Services Historic Market Size by Type (2020-2025)
4.2 Global Oncolytic Virus CDMO Services Forecasted Market Size by Type (2026-2031)
5 Oncolytic Virus CDMO Services Breakdown Data by Application
5.1 Global Oncolytic Virus CDMO Services Historic Market Size by Application (2020-2025)
5.2 Global Oncolytic Virus CDMO Services Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oncolytic Virus CDMO Services Market Size (2020-2031)
6.2 North America Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
6.4 North America Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncolytic Virus CDMO Services Market Size (2020-2031)
7.2 Europe Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
7.4 Europe Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus CDMO Services Market Size (2020-2031)
8.2 Asia-Pacific Oncolytic Virus CDMO Services Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2020-2025)
8.4 Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncolytic Virus CDMO Services Market Size (2020-2031)
9.2 Latin America Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
9.4 Latin America Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus CDMO Services Market Size (2020-2031)
10.2 Middle East & Africa Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
10.4 Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm (Vibalogics)
11.1.1 Recipharm (Vibalogics) Company Details
11.1.2 Recipharm (Vibalogics) Business Overview
11.1.3 Recipharm (Vibalogics) Oncolytic Virus CDMO Services Introduction
11.1.4 Recipharm (Vibalogics) Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.1.5 Recipharm (Vibalogics) Recent Development
11.2 IDT Biologika
11.2.1 IDT Biologika Company Details
11.2.2 IDT Biologika Business Overview
11.2.3 IDT Biologika Oncolytic Virus CDMO Services Introduction
11.2.4 IDT Biologika Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.2.5 IDT Biologika Recent Development
11.3 FUJIFILM Diosynth Biotechnologies
11.3.1 FUJIFILM Diosynth Biotechnologies Company Details
11.3.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.3.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Introduction
11.3.4 FUJIFILM Diosynth Biotechnologies Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.3.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.4 Exothera
11.4.1 Exothera Company Details
11.4.2 Exothera Business Overview
11.4.3 Exothera Oncolytic Virus CDMO Services Introduction
11.4.4 Exothera Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.4.5 Exothera Recent Development
11.5 Lonza
11.5.1 Lonza Company Details
11.5.2 Lonza Business Overview
11.5.3 Lonza Oncolytic Virus CDMO Services Introduction
11.5.4 Lonza Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.5.5 Lonza Recent Development
11.6 Creative Biolabs
11.6.1 Creative Biolabs Company Details
11.6.2 Creative Biolabs Business Overview
11.6.3 Creative Biolabs Oncolytic Virus CDMO Services Introduction
11.6.4 Creative Biolabs Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.6.5 Creative Biolabs Recent Development
11.7 Takara Bio
11.7.1 Takara Bio Company Details
11.7.2 Takara Bio Business Overview
11.7.3 Takara Bio Oncolytic Virus CDMO Services Introduction
11.7.4 Takara Bio Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.7.5 Takara Bio Recent Development
11.8 Libentech
11.8.1 Libentech Company Details
11.8.2 Libentech Business Overview
11.8.3 Libentech Oncolytic Virus CDMO Services Introduction
11.8.4 Libentech Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.8.5 Libentech Recent Development
11.9 ABL
11.9.1 ABL Company Details
11.9.2 ABL Business Overview
11.9.3 ABL Oncolytic Virus CDMO Services Introduction
11.9.4 ABL Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.9.5 ABL Recent Development
11.10 Nabios
11.10.1 Nabios Company Details
11.10.2 Nabios Business Overview
11.10.3 Nabios Oncolytic Virus CDMO Services Introduction
11.10.4 Nabios Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.10.5 Nabios Recent Development
11.11 Halix
11.11.1 Halix Company Details
11.11.2 Halix Business Overview
11.11.3 Halix Oncolytic Virus CDMO Services Introduction
11.11.4 Halix Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.11.5 Halix Recent Development
11.12 Obio Technology
11.12.1 Obio Technology Company Details
11.12.2 Obio Technology Business Overview
11.12.3 Obio Technology Oncolytic Virus CDMO Services Introduction
11.12.4 Obio Technology Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.12.5 Obio Technology Recent Development
11.13 Porton Advanced
11.13.1 Porton Advanced Company Details
11.13.2 Porton Advanced Business Overview
11.13.3 Porton Advanced Oncolytic Virus CDMO Services Introduction
11.13.4 Porton Advanced Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.13.5 Porton Advanced Recent Development
11.14 WuXi ATU
11.14.1 WuXi ATU Company Details
11.14.2 WuXi ATU Business Overview
11.14.3 WuXi ATU Oncolytic Virus CDMO Services Introduction
11.14.4 WuXi ATU Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.14.5 WuXi ATU Recent Development
11.15 Genevoyager
11.15.1 Genevoyager Company Details
11.15.2 Genevoyager Business Overview
11.15.3 Genevoyager Oncolytic Virus CDMO Services Introduction
11.15.4 Genevoyager Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.15.5 Genevoyager Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus CDMO Services Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oncolytic Herpes Simplex Virus
1.2.3 Oncolytic Adenovirus
1.2.4 Oncolytic Vaccinia Virus
1.2.5 Others
1.3 Market by Application
1.3.1 Global Oncolytic Virus CDMO Services Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 R&D
1.3.3 Biopharmaceutical Manufacturers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus CDMO Services Market Perspective (2020-2031)
2.2 Global Oncolytic Virus CDMO Services Growth Trends by Region
2.2.1 Global Oncolytic Virus CDMO Services Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oncolytic Virus CDMO Services Historic Market Size by Region (2020-2025)
2.2.3 Oncolytic Virus CDMO Services Forecasted Market Size by Region (2026-2031)
2.3 Oncolytic Virus CDMO Services Market Dynamics
2.3.1 Oncolytic Virus CDMO Services Industry Trends
2.3.2 Oncolytic Virus CDMO Services Market Drivers
2.3.3 Oncolytic Virus CDMO Services Market Challenges
2.3.4 Oncolytic Virus CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus CDMO Services Players by Revenue
3.1.1 Global Top Oncolytic Virus CDMO Services Players by Revenue (2020-2025)
3.1.2 Global Oncolytic Virus CDMO Services Revenue Market Share by Players (2020-2025)
3.2 Global Oncolytic Virus CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oncolytic Virus CDMO Services Revenue
3.4 Global Oncolytic Virus CDMO Services Market Concentration Ratio
3.4.1 Global Oncolytic Virus CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus CDMO Services Revenue in 2024
3.5 Global Key Players of Oncolytic Virus CDMO Services Head office and Area Served
3.6 Global Key Players of Oncolytic Virus CDMO Services, Product and Application
3.7 Global Key Players of Oncolytic Virus CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus CDMO Services Breakdown Data by Type
4.1 Global Oncolytic Virus CDMO Services Historic Market Size by Type (2020-2025)
4.2 Global Oncolytic Virus CDMO Services Forecasted Market Size by Type (2026-2031)
5 Oncolytic Virus CDMO Services Breakdown Data by Application
5.1 Global Oncolytic Virus CDMO Services Historic Market Size by Application (2020-2025)
5.2 Global Oncolytic Virus CDMO Services Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oncolytic Virus CDMO Services Market Size (2020-2031)
6.2 North America Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
6.4 North America Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncolytic Virus CDMO Services Market Size (2020-2031)
7.2 Europe Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
7.4 Europe Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus CDMO Services Market Size (2020-2031)
8.2 Asia-Pacific Oncolytic Virus CDMO Services Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2020-2025)
8.4 Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncolytic Virus CDMO Services Market Size (2020-2031)
9.2 Latin America Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
9.4 Latin America Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus CDMO Services Market Size (2020-2031)
10.2 Middle East & Africa Oncolytic Virus CDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2020-2025)
10.4 Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm (Vibalogics)
11.1.1 Recipharm (Vibalogics) Company Details
11.1.2 Recipharm (Vibalogics) Business Overview
11.1.3 Recipharm (Vibalogics) Oncolytic Virus CDMO Services Introduction
11.1.4 Recipharm (Vibalogics) Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.1.5 Recipharm (Vibalogics) Recent Development
11.2 IDT Biologika
11.2.1 IDT Biologika Company Details
11.2.2 IDT Biologika Business Overview
11.2.3 IDT Biologika Oncolytic Virus CDMO Services Introduction
11.2.4 IDT Biologika Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.2.5 IDT Biologika Recent Development
11.3 FUJIFILM Diosynth Biotechnologies
11.3.1 FUJIFILM Diosynth Biotechnologies Company Details
11.3.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.3.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Introduction
11.3.4 FUJIFILM Diosynth Biotechnologies Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.3.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.4 Exothera
11.4.1 Exothera Company Details
11.4.2 Exothera Business Overview
11.4.3 Exothera Oncolytic Virus CDMO Services Introduction
11.4.4 Exothera Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.4.5 Exothera Recent Development
11.5 Lonza
11.5.1 Lonza Company Details
11.5.2 Lonza Business Overview
11.5.3 Lonza Oncolytic Virus CDMO Services Introduction
11.5.4 Lonza Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.5.5 Lonza Recent Development
11.6 Creative Biolabs
11.6.1 Creative Biolabs Company Details
11.6.2 Creative Biolabs Business Overview
11.6.3 Creative Biolabs Oncolytic Virus CDMO Services Introduction
11.6.4 Creative Biolabs Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.6.5 Creative Biolabs Recent Development
11.7 Takara Bio
11.7.1 Takara Bio Company Details
11.7.2 Takara Bio Business Overview
11.7.3 Takara Bio Oncolytic Virus CDMO Services Introduction
11.7.4 Takara Bio Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.7.5 Takara Bio Recent Development
11.8 Libentech
11.8.1 Libentech Company Details
11.8.2 Libentech Business Overview
11.8.3 Libentech Oncolytic Virus CDMO Services Introduction
11.8.4 Libentech Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.8.5 Libentech Recent Development
11.9 ABL
11.9.1 ABL Company Details
11.9.2 ABL Business Overview
11.9.3 ABL Oncolytic Virus CDMO Services Introduction
11.9.4 ABL Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.9.5 ABL Recent Development
11.10 Nabios
11.10.1 Nabios Company Details
11.10.2 Nabios Business Overview
11.10.3 Nabios Oncolytic Virus CDMO Services Introduction
11.10.4 Nabios Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.10.5 Nabios Recent Development
11.11 Halix
11.11.1 Halix Company Details
11.11.2 Halix Business Overview
11.11.3 Halix Oncolytic Virus CDMO Services Introduction
11.11.4 Halix Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.11.5 Halix Recent Development
11.12 Obio Technology
11.12.1 Obio Technology Company Details
11.12.2 Obio Technology Business Overview
11.12.3 Obio Technology Oncolytic Virus CDMO Services Introduction
11.12.4 Obio Technology Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.12.5 Obio Technology Recent Development
11.13 Porton Advanced
11.13.1 Porton Advanced Company Details
11.13.2 Porton Advanced Business Overview
11.13.3 Porton Advanced Oncolytic Virus CDMO Services Introduction
11.13.4 Porton Advanced Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.13.5 Porton Advanced Recent Development
11.14 WuXi ATU
11.14.1 WuXi ATU Company Details
11.14.2 WuXi ATU Business Overview
11.14.3 WuXi ATU Oncolytic Virus CDMO Services Introduction
11.14.4 WuXi ATU Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.14.5 WuXi ATU Recent Development
11.15 Genevoyager
11.15.1 Genevoyager Company Details
11.15.2 Genevoyager Business Overview
11.15.3 Genevoyager Oncolytic Virus CDMO Services Introduction
11.15.4 Genevoyager Revenue in Oncolytic Virus CDMO Services Business (2020-2025)
11.15.5 Genevoyager Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Oncolytic Virus CDMO Services Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oncolytic Herpes Simplex Virus
Table 3. Key Players of Oncolytic Adenovirus
Table 4. Key Players of Oncolytic Vaccinia Virus
Table 5. Key Players of Others
Table 6. Global Oncolytic Virus CDMO Services Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Oncolytic Virus CDMO Services Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Oncolytic Virus CDMO Services Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Oncolytic Virus CDMO Services Market Share by Region (2020-2025)
Table 10. Global Oncolytic Virus CDMO Services Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Oncolytic Virus CDMO Services Market Share by Region (2026-2031)
Table 12. Oncolytic Virus CDMO Services Market Trends
Table 13. Oncolytic Virus CDMO Services Market Drivers
Table 14. Oncolytic Virus CDMO Services Market Challenges
Table 15. Oncolytic Virus CDMO Services Market Restraints
Table 16. Global Oncolytic Virus CDMO Services Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Oncolytic Virus CDMO Services Market Share by Players (2020-2025)
Table 18. Global Top Oncolytic Virus CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus CDMO Services as of 2024)
Table 19. Ranking of Global Top Oncolytic Virus CDMO Services Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Oncolytic Virus CDMO Services Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Oncolytic Virus CDMO Services, Headquarters and Area Served
Table 22. Global Key Players of Oncolytic Virus CDMO Services, Product and Application
Table 23. Global Key Players of Oncolytic Virus CDMO Services, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Oncolytic Virus CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Oncolytic Virus CDMO Services Revenue Market Share by Type (2020-2025)
Table 27. Global Oncolytic Virus CDMO Services Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Oncolytic Virus CDMO Services Revenue Market Share by Type (2026-2031)
Table 29. Global Oncolytic Virus CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Oncolytic Virus CDMO Services Revenue Market Share by Application (2020-2025)
Table 31. Global Oncolytic Virus CDMO Services Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Oncolytic Virus CDMO Services Revenue Market Share by Application (2026-2031)
Table 33. North America Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Oncolytic Virus CDMO Services Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 48. Recipharm (Vibalogics) Company Details
Table 49. Recipharm (Vibalogics) Business Overview
Table 50. Recipharm (Vibalogics) Oncolytic Virus CDMO Services Product
Table 51. Recipharm (Vibalogics) Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 52. Recipharm (Vibalogics) Recent Development
Table 53. IDT Biologika Company Details
Table 54. IDT Biologika Business Overview
Table 55. IDT Biologika Oncolytic Virus CDMO Services Product
Table 56. IDT Biologika Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 57. IDT Biologika Recent Development
Table 58. FUJIFILM Diosynth Biotechnologies Company Details
Table 59. FUJIFILM Diosynth Biotechnologies Business Overview
Table 60. FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Product
Table 61. FUJIFILM Diosynth Biotechnologies Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 62. FUJIFILM Diosynth Biotechnologies Recent Development
Table 63. Exothera Company Details
Table 64. Exothera Business Overview
Table 65. Exothera Oncolytic Virus CDMO Services Product
Table 66. Exothera Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 67. Exothera Recent Development
Table 68. Lonza Company Details
Table 69. Lonza Business Overview
Table 70. Lonza Oncolytic Virus CDMO Services Product
Table 71. Lonza Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 72. Lonza Recent Development
Table 73. Creative Biolabs Company Details
Table 74. Creative Biolabs Business Overview
Table 75. Creative Biolabs Oncolytic Virus CDMO Services Product
Table 76. Creative Biolabs Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 77. Creative Biolabs Recent Development
Table 78. Takara Bio Company Details
Table 79. Takara Bio Business Overview
Table 80. Takara Bio Oncolytic Virus CDMO Services Product
Table 81. Takara Bio Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 82. Takara Bio Recent Development
Table 83. Libentech Company Details
Table 84. Libentech Business Overview
Table 85. Libentech Oncolytic Virus CDMO Services Product
Table 86. Libentech Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 87. Libentech Recent Development
Table 88. ABL Company Details
Table 89. ABL Business Overview
Table 90. ABL Oncolytic Virus CDMO Services Product
Table 91. ABL Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 92. ABL Recent Development
Table 93. Nabios Company Details
Table 94. Nabios Business Overview
Table 95. Nabios Oncolytic Virus CDMO Services Product
Table 96. Nabios Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 97. Nabios Recent Development
Table 98. Halix Company Details
Table 99. Halix Business Overview
Table 100. Halix Oncolytic Virus CDMO Services Product
Table 101. Halix Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 102. Halix Recent Development
Table 103. Obio Technology Company Details
Table 104. Obio Technology Business Overview
Table 105. Obio Technology Oncolytic Virus CDMO Services Product
Table 106. Obio Technology Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 107. Obio Technology Recent Development
Table 108. Porton Advanced Company Details
Table 109. Porton Advanced Business Overview
Table 110. Porton Advanced Oncolytic Virus CDMO Services Product
Table 111. Porton Advanced Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 112. Porton Advanced Recent Development
Table 113. WuXi ATU Company Details
Table 114. WuXi ATU Business Overview
Table 115. WuXi ATU Oncolytic Virus CDMO Services Product
Table 116. WuXi ATU Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 117. WuXi ATU Recent Development
Table 118. Genevoyager Company Details
Table 119. Genevoyager Business Overview
Table 120. Genevoyager Oncolytic Virus CDMO Services Product
Table 121. Genevoyager Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 122. Genevoyager Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Oncolytic Virus CDMO Services Picture
Figure 2. Global Oncolytic Virus CDMO Services Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oncolytic Virus CDMO Services Market Share by Type: 2024 VS 2031
Figure 4. Oncolytic Herpes Simplex Virus Features
Figure 5. Oncolytic Adenovirus Features
Figure 6. Oncolytic Vaccinia Virus Features
Figure 7. Others Features
Figure 8. Global Oncolytic Virus CDMO Services Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Oncolytic Virus CDMO Services Market Share by Application: 2024 VS 2031
Figure 10. R&D Case Studies
Figure 11. Biopharmaceutical Manufacturers Case Studies
Figure 12. Others Case Studies
Figure 13. Oncolytic Virus CDMO Services Report Years Considered
Figure 14. Global Oncolytic Virus CDMO Services Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Oncolytic Virus CDMO Services Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Oncolytic Virus CDMO Services Market Share by Region: 2024 VS 2031
Figure 17. Global Oncolytic Virus CDMO Services Market Share by Players in 2024
Figure 18. Global Top Oncolytic Virus CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus CDMO Services as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Oncolytic Virus CDMO Services Revenue in 2024
Figure 20. North America Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 22. United States Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 26. Germany Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Oncolytic Virus CDMO Services Market Share by Region (2020-2031)
Figure 34. China Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 42. Mexico Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 46. Turkey Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Recipharm (Vibalogics) Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 50. IDT Biologika Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 52. Exothera Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 53. Lonza Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 54. Creative Biolabs Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 55. Takara Bio Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 56. Libentech Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 57. ABL Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 58. Nabios Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 59. Halix Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 60. Obio Technology Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 61. Porton Advanced Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 62. WuXi ATU Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 63. Genevoyager Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Oncolytic Virus CDMO Services Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oncolytic Herpes Simplex Virus
Table 3. Key Players of Oncolytic Adenovirus
Table 4. Key Players of Oncolytic Vaccinia Virus
Table 5. Key Players of Others
Table 6. Global Oncolytic Virus CDMO Services Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Oncolytic Virus CDMO Services Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Oncolytic Virus CDMO Services Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Oncolytic Virus CDMO Services Market Share by Region (2020-2025)
Table 10. Global Oncolytic Virus CDMO Services Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Oncolytic Virus CDMO Services Market Share by Region (2026-2031)
Table 12. Oncolytic Virus CDMO Services Market Trends
Table 13. Oncolytic Virus CDMO Services Market Drivers
Table 14. Oncolytic Virus CDMO Services Market Challenges
Table 15. Oncolytic Virus CDMO Services Market Restraints
Table 16. Global Oncolytic Virus CDMO Services Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Oncolytic Virus CDMO Services Market Share by Players (2020-2025)
Table 18. Global Top Oncolytic Virus CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus CDMO Services as of 2024)
Table 19. Ranking of Global Top Oncolytic Virus CDMO Services Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Oncolytic Virus CDMO Services Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Oncolytic Virus CDMO Services, Headquarters and Area Served
Table 22. Global Key Players of Oncolytic Virus CDMO Services, Product and Application
Table 23. Global Key Players of Oncolytic Virus CDMO Services, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Oncolytic Virus CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Oncolytic Virus CDMO Services Revenue Market Share by Type (2020-2025)
Table 27. Global Oncolytic Virus CDMO Services Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Oncolytic Virus CDMO Services Revenue Market Share by Type (2026-2031)
Table 29. Global Oncolytic Virus CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Oncolytic Virus CDMO Services Revenue Market Share by Application (2020-2025)
Table 31. Global Oncolytic Virus CDMO Services Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Oncolytic Virus CDMO Services Revenue Market Share by Application (2026-2031)
Table 33. North America Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Oncolytic Virus CDMO Services Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Oncolytic Virus CDMO Services Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Oncolytic Virus CDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Oncolytic Virus CDMO Services Market Size by Country (2026-2031) & (US$ Million)
Table 48. Recipharm (Vibalogics) Company Details
Table 49. Recipharm (Vibalogics) Business Overview
Table 50. Recipharm (Vibalogics) Oncolytic Virus CDMO Services Product
Table 51. Recipharm (Vibalogics) Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 52. Recipharm (Vibalogics) Recent Development
Table 53. IDT Biologika Company Details
Table 54. IDT Biologika Business Overview
Table 55. IDT Biologika Oncolytic Virus CDMO Services Product
Table 56. IDT Biologika Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 57. IDT Biologika Recent Development
Table 58. FUJIFILM Diosynth Biotechnologies Company Details
Table 59. FUJIFILM Diosynth Biotechnologies Business Overview
Table 60. FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Product
Table 61. FUJIFILM Diosynth Biotechnologies Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 62. FUJIFILM Diosynth Biotechnologies Recent Development
Table 63. Exothera Company Details
Table 64. Exothera Business Overview
Table 65. Exothera Oncolytic Virus CDMO Services Product
Table 66. Exothera Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 67. Exothera Recent Development
Table 68. Lonza Company Details
Table 69. Lonza Business Overview
Table 70. Lonza Oncolytic Virus CDMO Services Product
Table 71. Lonza Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 72. Lonza Recent Development
Table 73. Creative Biolabs Company Details
Table 74. Creative Biolabs Business Overview
Table 75. Creative Biolabs Oncolytic Virus CDMO Services Product
Table 76. Creative Biolabs Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 77. Creative Biolabs Recent Development
Table 78. Takara Bio Company Details
Table 79. Takara Bio Business Overview
Table 80. Takara Bio Oncolytic Virus CDMO Services Product
Table 81. Takara Bio Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 82. Takara Bio Recent Development
Table 83. Libentech Company Details
Table 84. Libentech Business Overview
Table 85. Libentech Oncolytic Virus CDMO Services Product
Table 86. Libentech Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 87. Libentech Recent Development
Table 88. ABL Company Details
Table 89. ABL Business Overview
Table 90. ABL Oncolytic Virus CDMO Services Product
Table 91. ABL Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 92. ABL Recent Development
Table 93. Nabios Company Details
Table 94. Nabios Business Overview
Table 95. Nabios Oncolytic Virus CDMO Services Product
Table 96. Nabios Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 97. Nabios Recent Development
Table 98. Halix Company Details
Table 99. Halix Business Overview
Table 100. Halix Oncolytic Virus CDMO Services Product
Table 101. Halix Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 102. Halix Recent Development
Table 103. Obio Technology Company Details
Table 104. Obio Technology Business Overview
Table 105. Obio Technology Oncolytic Virus CDMO Services Product
Table 106. Obio Technology Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 107. Obio Technology Recent Development
Table 108. Porton Advanced Company Details
Table 109. Porton Advanced Business Overview
Table 110. Porton Advanced Oncolytic Virus CDMO Services Product
Table 111. Porton Advanced Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 112. Porton Advanced Recent Development
Table 113. WuXi ATU Company Details
Table 114. WuXi ATU Business Overview
Table 115. WuXi ATU Oncolytic Virus CDMO Services Product
Table 116. WuXi ATU Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 117. WuXi ATU Recent Development
Table 118. Genevoyager Company Details
Table 119. Genevoyager Business Overview
Table 120. Genevoyager Oncolytic Virus CDMO Services Product
Table 121. Genevoyager Revenue in Oncolytic Virus CDMO Services Business (2020-2025) & (US$ Million)
Table 122. Genevoyager Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Oncolytic Virus CDMO Services Picture
Figure 2. Global Oncolytic Virus CDMO Services Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oncolytic Virus CDMO Services Market Share by Type: 2024 VS 2031
Figure 4. Oncolytic Herpes Simplex Virus Features
Figure 5. Oncolytic Adenovirus Features
Figure 6. Oncolytic Vaccinia Virus Features
Figure 7. Others Features
Figure 8. Global Oncolytic Virus CDMO Services Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Oncolytic Virus CDMO Services Market Share by Application: 2024 VS 2031
Figure 10. R&D Case Studies
Figure 11. Biopharmaceutical Manufacturers Case Studies
Figure 12. Others Case Studies
Figure 13. Oncolytic Virus CDMO Services Report Years Considered
Figure 14. Global Oncolytic Virus CDMO Services Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Oncolytic Virus CDMO Services Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Oncolytic Virus CDMO Services Market Share by Region: 2024 VS 2031
Figure 17. Global Oncolytic Virus CDMO Services Market Share by Players in 2024
Figure 18. Global Top Oncolytic Virus CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus CDMO Services as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Oncolytic Virus CDMO Services Revenue in 2024
Figure 20. North America Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 22. United States Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 26. Germany Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Oncolytic Virus CDMO Services Market Share by Region (2020-2031)
Figure 34. China Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 42. Mexico Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Oncolytic Virus CDMO Services Market Share by Country (2020-2031)
Figure 46. Turkey Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Oncolytic Virus CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Recipharm (Vibalogics) Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 50. IDT Biologika Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 52. Exothera Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 53. Lonza Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 54. Creative Biolabs Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 55. Takara Bio Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 56. Libentech Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 57. ABL Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 58. Nabios Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 59. Halix Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 60. Obio Technology Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 61. Porton Advanced Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 62. WuXi ATU Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 63. Genevoyager Revenue Growth Rate in Oncolytic Virus CDMO Services Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Krypton Flash Lamp Market Research Report 2025
May 12, 25
Global IR Halogen Lamp Market Research Report 2025
May 12, 25
Global Halogen IR Lamp Market Research Report 2025
May 12, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232